SCHEMBL4417636

SCHEMBL4417636

Oc1ncnc2cc(Cl)ccc12

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NR4A2 P43354 1/20 0.47
SOS2 Q07890 1/20 0.47
CYP1A2 P05177 2/20 0.45
CYP2D6 P10635 1/20 0.45
ALDH1A1 P00352 2/20 0.44
MAPT P10636 2/20 0.44
GAA P10253 1/20 0.44
ATM Q13315 1/20 0.44
KDM4E B2RXH2 1/20 0.43
HPGD P15428 1/20 0.43
HTT P42858 3/20 0.42
LMNA P02545 2/20 0.42
SMN1; SMN2 Q16637 2/20 0.42
KMT2A Q03164 2/20 0.42
MEN1 O00255 1/20 0.42
PPARG P37231 1/20 0.42
RXFP1 Q9HBX9 1/20 0.42
NR2E3 Q9Y5X4 1/20 0.42
NCOR2 Q9Y618 1/20 0.42
NPC1 O15118 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL16061044 0.98 NR4A2 (0.46) NR4A2SOS2CYP1A2CYP2D6ALDH1A1
SCHEMBL3734931 0.84 HTT (0.49) NR4A2CYP1A2CYP2D6ALDH1A1MAPT
Ethoxycarbonyl Group SCHEMBL27863232 0.81 HTT (0.39) CYP1A2CYP2D6ALDH1A1ATMKDM4E
SCHEMBL29416410 0.79 PDE4A (0.57) NR4A2SOS2CYP1A2CYP2D6ALDH1A1
SCHEMBL401110 0.79 PDE4A (0.57) NR4A2SOS2CYP1A2CYP2D6ALDH1A1
SCHEMBL5453911 0.79 EGFR (0.46) ALDH1A1MAPTKDM4EHPGDHTT
Hydrochloric Acid SCHEMBL5739823 0.78 PDE4A (0.55) NR4A2SOS2CYP1A2CYP2D6ALDH1A1
SCHEMBL2082154 0.76 EGFR (0.51) HTTLMNAKMT2AMEN1
SCHEMBL13702434 0.76 EGFR (0.32)
SCHEMBL6442231 0.76 NR4A2 (0.56) NR4A2SOS2CYP1A2CYP2D6ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-117209436-A Preparation method of dacatinib key intermediate 江苏海洋大学 2023-12-12 CN disclosed
CN-111116552-B Quinazolinone compound and preparation method thereof 河北科技大学 2022-10-11 CN disclosed
CN-111116552-A Quinazolinone compound and preparation method thereof 河北科技大学 2020-05-08 CN disclosed
CN-104774184-A Alpha-cyano-alpha, beta-unsaturated amide compound and medical application thereof UNIV CHINA PHARMA 2015-07-15 CN disclosed
CN-102838550-B Quinolinylcrotyl compound and its application in preparation of anti-malignant tumor drugs METABOMICS INC. (CN) 2014-10-01 CN disclosed
WO-2014145512-A2 POTENT SMALL MOLECULE INHIBITORS OF AUTOPHAGY, AND METHODS OF USE THEREOF PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) 2014-09-18 WO disclosed
CN-101899011-B Dithiocarbamates compound, preparation method and application thereof UNIV BEIJING 2013-01-16 CN disclosed
CN-102838550-A Quinolinylcrotyl compound and its application in preparation of anti-malignant tumor drugs SUZHOU METABOMICS INC 2012-12-26 CN disclosed
CN-101899011-A Dithiocarbamates compound, preparation method and application thereof UNIV BEIJING 2010-12-01 CN disclosed
EP-1606255-B1 CYCLIC DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY BRISTOL MYERS SQUIBB CO (US) 2009-11-11 EP disclosed
EP-2098508-A1 Cyclic derivatives as modulators of chemokine receptor activity Bristol-Myers Squibb Company (US) 2009-09-09 EP disclosed
US-20080114052-A1 CYCLIC DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY BRISTOL-MYERS SQUIBB COMPANY 2008-05-15 US disclosed
US-7338947-B2 Cyclic derivatives as modulators of chemokine receptor activity BRISTOL-MYERS SQUIBB CO. (US) 2008-03-04 US disclosed
US-7183270-B2 Cyclic derivatives as modulators of chemokine receptor activity BRISTOL-MYERS SQUIBB COMPANY (US) 2007-02-27 US disclosed
US-20070032541-A1 Cyclic derivatives as modulators of chemokine receptor activity CHERNEY ROBERT J 2007-02-08 US disclosed
EP-1606255-A4 CYCLIC DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY BRISTOL MYERS SQUIBB CO (US) 2007-02-07 EP disclosed
EP-1606255-A2 CYCLIC DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY Bristol-Myers Squibb Company (US) 2005-12-21 EP disclosed
US-20040186140-A1 Cyclic derivatives as modulators of chemokine receptor activity BRISTOL-MYERS SQUIBB COMPANY 2004-09-23 US disclosed
WO-2004071460-A2 CYCLIC DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY BRISTOL-MYERS SQUIBB COMPANY (US) 2004-08-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080114052-A1 CYCLIC DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY CCL11, CCL2, CCR1 NR4A2 1241/4885SOS2 3504/4885CYP1A2 3221/4885
US-20040186140-A1 Cyclic derivatives as modulators of chemokine receptor activity CCL11, CCR1, CCL2 NR4A2 1237/4885SOS2 3514/4885CYP1A2 3163/4885
US-20070032541-A1 Cyclic derivatives as modulators of chemokine receptor activity CCL11, CCL2, CCR1 NR4A2 1241/4885SOS2 3504/4885CYP1A2 3221/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.